Literature DB >> 2504679

Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes.

J Hsia1, N Sarin, J H Oliver, A L Goldstein.   

Abstract

Interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) have recently been added to the arsenal of synthetic biological response modifiers with important immunomodulatory activities. In this paper we have assessed the effects of acetylsalicylic acid (aspirin), thymosin alpha and thymosin fraction 5 (TF5), a partially purified calf thymic preparation, on production of IFN-gamma in vitro. Stimulation by oral aspirin of IL-2 and IFN-gamma production by peripheral blood lymphocytes (PBLs) was also studied in healthy human volunteers. Aspirin, thymosin alpha 1 and TF5 were all observed to enhance phytohemagglutinin (PHA)-stimulated production of IFN-gamma. Peak IFN-gamma production by PHA-stimulated PBLs was observed after 24 h of incubation with TF5 and after 72 h with aspirin. Stimulation by aspirin and TF5 required the presence of macrophages, and was additive and dose-dependent. The additive effects of aspirin and TF5 suggest that these agents act by different mechanisms. Oral administration of aspirin in normal volunteers significantly enhanced production of both IFN-gamma and IL-2. PHA-stimulated IFN-gamma production was greatest 24 h after aspirin ingestion; in contrast, IL-2 production was optimal 10 h after aspirin ingestion. These observations suggest that oral aspirin is an effective biological response modifier in humans and raise the possibility of a novel combination approach to immunomodulation involving cyclooxygenase inhibitors and thymosins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504679     DOI: 10.1016/0162-3109(89)90045-3

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  12 in total

1.  Cyclooxygenase-1 and -2 are expressed by human T cells.

Authors:  J L Pablos; B Santiago; P E Carreira; M Galindo; J J Gomez-Reino
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Aspirin and risk of fatal colon cancer.

Authors:  M Odeh
Journal:  Postgrad Med J       Date:  1993-03       Impact factor: 2.401

3.  A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Robert G Gish; Stuart C Gordon; David Nelson; Vinod Rustgi; Israel Rios
Journal:  Hepatol Int       Date:  2009-05-08       Impact factor: 6.047

Review 4.  Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).

Authors:  Xianyao Wang; Zhixu He; Xing Zhao
Journal:  Exp Ther Med       Date:  2021-02-03       Impact factor: 2.447

5.  Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.

Authors:  Daryl J Kor; Rickey E Carter; Pauline K Park; Emir Festic; Valerie M Banner-Goodspeed; Richard Hinds; Daniel Talmor; Ognjen Gajic; Lorraine B Ware; Michelle Ng Gong
Journal:  JAMA       Date:  2016-06-14       Impact factor: 56.272

Review 6.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

7.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

8.  Acetylsalicylic acid has no effects on various isolated immune cells in vitro.

Authors:  G Uhlenbruck; H Lötzerich; J Bernhardt; K Rogalla
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1993

9.  Influence of acetylsalicylic acid on a Listeria monocytogenes infection.

Authors:  S Hockertz; I Paulini; K Rogalla; T Schettler
Journal:  Agents Actions       Date:  1993-09

10.  Role of Acetylsalicylic Acid in Cytokine Stimulation of Macrophages in Antibody-Dependent Cellular Cytotoxicity (ADCC).

Authors:  M Jäpel; H Lötzerich; K Rogalla
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.